ClinicalTrials.gg
Not yet recruitingNCT07499479Naming-DecoderUpdated Mar 30, 2026

Picture Naming Decoding From Intraoperative Recordings

An interventional study of Placement of high-density electrodes on cortical surface during awake surgery and Placement of INBRAIN Graphene Cortical Interface on cortical surface in Brain Tumor Adult, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Brain Neoplasms by Assistance Publique - Hôpitaux de Paris — 5 open to participants now, 5 under way, none of them phase 3. Brain Neoplasms · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
10th of 11
20 · median 60
Started
2026
the only one that year
No phase
4 of 15
3 open now
Registered
15th of 15
by date

Among the 15 studies in Brain Neoplasms by Assistance Publique - Hôpitaux de Paris, this one is the 10th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is one of 4 with no phase, and was the 15th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

5 of the 15 studies in Brain Neoplasms by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Brain Neoplasms by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The clinical investigation evaluates whether speech can be decoded from neural activity recorded with cortical surface electrocorticography (ECoG) electrodes during awake brain tumor surgery. Neural signals and voice recordings are collected while patients perform a picture naming task as part of standard intraoperative mapping. The study assesses the ability of machine learning algorithms to predict the named item from intraoperative electrophysiological recordings.

Read the detailed description

Patients with severe speech and motor impairments often lose the ability to communicate, detrimentally affecting their quality of life. Invasive brain-computer interfaces (BCIs) have shown promise in restoring lost speech functionalities by decoding neural activity of intended or attempted speech. However, the systems with the most promising results rely on highly invasive micro-electrode arrays that tend to irritate the brain tissue leading to inflammation, tissue scarring and ultimately, loss of signal. A promising long-term alternative is intracranial electrode strips/grids that rest on the surface of the brain without having to penetrate the cortex. The contact density of standard strips/grids used for electrophysiological mapping is very low (1 contact/cm2 compared to 100 contacts/cm2), however, a new generation of electrode strips/grids offer decent contact density closing the distance with micro-electrode arrays. In order to determine if the contact density of cortical surface electrode grids is sufficient for decoding speech, we aim to record and decode neural activity of tumor patients performing a picture naming task during awake surgeries, as these operations offer the only opportunity to test the use of cortical surface electrodes for neural speech decoding.

03

Conditions studied

  • Brain Tumor Adult

Browse trials for

04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients 18 years of age or older.
  2. Patients with a brain tumor requiring surgery under "awake" conditions with intraoperative placement of ECoG electrodes at Lariboisière Hospital.

3 -Patients with tumor locations close to language processing areas. 4 -Patients having given consent during the interview with the neurosurgeon.

Exclusion criteria

Exclusion Criteria:

  1. Patients with severe cognitive impairments that would prevent understanding and performing the image-naming task,
  2. Patients with major psychiatric disorders that could affect their ability to participate in the research,
  3. Patients with inoperable tumors,
  4. Patients with tumor locations incompatible with safe or effective placement of ECoG electrodes,
  5. Females that are breastfeeding or females with with positive urine pregnancy test or not using adequate ,
  6. Patients unable to provide due to cognitive or language limitations,
  7. Patients who have any electrical stimulator or any active implanted medical device that uses high magnetic or electrical currents (e.g. patients with pacemaker defibrillator, neurostimulator, drugs pumps, retinal and cochlear device),
  8. Any wearable medical device that may cause troubles to the devices and injuries to the participants,
  9. Patients with medical to general or local anesthesia required for surgery,
  10. Patients with an active infection or infectious skin lesions on the scalp,
  11. Patients with a current use or a recent history of illicit drug(s) use or alcohol abuse (defined as frequent or daily consumption of more than four alcoholic drinks per day),
  12. Patients with contraindications to any surgical procedure,
  13. Patients undergoing treatment with anticoagulants, aggregation inhibitors, or non-steroidal anti-inflammatory drugs,
  14. Patients who decline to participate in the study,
  15. Any specially protected person: adults protected by law; persons hospitalized without their consent, at the request of a third party or ex officio; persons deprived of their liberty by a judicial decision,
  16. Participation in another interventional study or being in the exclusion period at the end of a previous study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    INBRAIN Graphene Cortical Interface (Non-CE-marked Class III )

    10 patients receive high-density electrodes.

    Procedure: Placement of high-density electrodes on cortical surface during awake surgery · Procedure: Placement of INBRAIN Graphene Cortical Interface on cortical surface

  • Active comparator
    DIXI C10-12BIOM and WISE WCS00-4S10-000 (CE-marked Class III)

    10 patients receive strandard low-density electrodes.

    Procedure: Placement of low-density electodes during awake brain surgery

Interventions

  • ProcedurePlacement of high-density electrodes on cortical surface during awake surgery

    INBRAIN Graphene Cortical Interface (Non-CE-marked Class III )high-density graphene ECoG grid placed on cortical surface for up to 2 hours during awake surgery. Recording only, no stimulation.

  • ProcedurePlacement of INBRAIN Graphene Cortical Interface on cortical surface

    INBRAIN Graphene Cortical Interface (Non-CE-marked Class III )high-density graphene ECoG grid placed on cortical surface for up to 2 hours during awake brain surgery. Recording only, no stimulation.

  • ProcedurePlacement of low-density electodes during awake brain surgery

    DIXI C10-12BIOM and WISE WCS00-4S10-000 (CE-marked Class III) low-density ECoG strips placed on cortical surface for up to 2 hours during awake surgery. Recording only, no stimulation.

06

What researchers measure

Primary outcomes

  1. Primary outcome Measure

    The primary metric for evaluating the success of the project is the accuracy of the machine learning algorithms in decoding neural activity to predict the named item by the patient. Achieving an Area Under the Curve (AUC) value of greater than 0.9 indicates high predictive performance.

    Time frame: Up to 12 months after the last patient's intraoperative recording

Secondary outcomes

  1. Secondary Outcome Measure

    The evaluation criterion is to identify axono-cortical evoked potentials (ACEPs) with a signal- to-noise ratio \> 1. The parameters consist of all recordings made by surface electrodes during axonal electrical stimulation at 1 Hz. On each channel, averaging will be performed, synchronized with the 1 Hz stimulation.

    Time frame: Up to 12 months after the last patient's intraoperative recording

07

Study locations

1 site
  • Department of neurosurgery Lariboisière hospital-APHP
    Paris, Île-de-France Region 75010, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Oct 2029, 42 months later.

Of 310 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 42 months is below that.

Counting every sponsor, half of 321 studies reached it within 64 months; a quarter within 35 and three quarters within 125.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Mar 30, 2026
StartEst.
Apr 15, 2026
Primary completionEst.
Oct 15, 2029
CompletionEst.
Oct 15, 2030
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07499479
Responsible party
Sponsor
First posted
Mar 30, 2026
Start date
Apr 15, 2026 (estimated)
Primary completion
Oct 15, 2029 (estimated)
Completion
Oct 15, 2030 (estimated)
Last update
Mar 30, 2026

Study contacts

Emmanuel MANDONNET
Contact
emmanuel.mandonnet@aphp.fr
0149958146 ext. Ext 33
Anne-Lise GIRAUD
Contact
anne-lise.giraud-mamessier@pasteur.fr
0176535060

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion